Kexing Biopharm Co., Ltd. (SHA:688136)

Market Cap	6.17B +34.2%
Revenue (ttm)	1.54B +9.5%
Net Income	159.44M +406.5%
EPS	0.81 +406.3%
Shares Out	198.11M
PE Ratio	38.43
Forward PE	n/a
Dividend	0.08 (0.26%)
Ex-Dividend Date	n/a

Volume	4,563,254
Average Volume	6,796,146
Open	31.03
Previous Close	31.13
Day's Range	29.73 - 31.21
52-Week Range	24.56 - 63.99
Beta	0.68
RSI	47.86
Earnings Date	Apr 22, 2026

About Kexing Biopharm

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b in...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 971
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688136

Financial Performance

In 2025, Kexing Biopharm's revenue was 1.54 billion, an increase of 9.54% compared to the previous year's 1.41 billion. Earnings were 159.44 million, an increase of 406.47%.